trending Market Intelligence /marketintelligence/en/news-insights/trending/z5-nlbXFLy2k8WI_0U59eg2 content esgSubNav
In This List

ImmunoGen licenses compounds for $30M

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


ImmunoGen licenses compounds for $30M

ImmunoGen Inc. agreed to license some of its compounds to Sanofi for a $30 million payment.

The compounds were developed by Sanofi using ImmunoGen's technology. They are five in total: SAR650984, SAR566658, SAR408701 and SAR428926 for the treatment of certain types of tumors, including triple negative breast cancer, and an antibody-drug conjugate being directed to an undisclosed target.

ImmunoGen also agreed to forgo future milestone and royalty payments in exchange for the payment.